Effect of a treatment strategy utilising Golimumab, Methotrexate and Corticosteroids versus Methotrexate and Corticosteroids in early, untreated Psoriatic Arthritis: results from the GOLMePsA investigator-initiated, single centre, double-blind, parallel-group, randomised controlled trial
COATES L. et al, (2025), The Lancet Rheumatology
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review
COATES L. et al, (2025), Advances in Therapy
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Study Nested Within an English and Welsh Audit Dataset
Charlton RA. et al, (2025), Annals of the Rheumatic Diseases
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
Jethwa H. et al, (2025), Rheumatology (Oxford)
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study
James L. et al, (2025), The Journal of Rheumatology, jrheum.2024 - 1035.C1
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study.
James L. et al, (2025), J Rheumatol
Association of clinical variables with methotrexate response in patients with psoriatic arthritis.
Kasiem FR. et al, (2025), Scand J Rheumatol, 1 - 8
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
López-Medina C. et al, (2025), Rheumatology (Oxford)
Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.
McGagh D. et al, (2025), Lancet Rheumatol, 7, e55 - e63
Psoriatic Arthritis Priority Setting Partnership: patient and clinician informed considerations for future UK health service delivery
James L. et al, (2024), Rheumatology
Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
Ahmed S. et al, (2024), Rheumatology Advances in Practice
The impact of psoriatic arthritis on quality of life: A systematic review
James L. et al, (2024), Therapeutic Advances in Musculoskeletal Disease
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial
Kavanaugh A. et al, (2024), Rheumatology